Streetbeat News

Regulatory

SPY

VGK

US Treasury Secretary Janet Yellen has stated that the Biden administration will ensure 'robust' support for Ukraine is not interrupted. She also applauded the EU's plan for a €50B Ukraine facility, emphasizing that economic aid to Ukraine should be as concessionary as possible.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2023 | 12:22 pm

SPY

VGK

U.S. Treasury Secretary Yellen has stated that support for Ukraine remains a 'top priority' for the U.S. and Europe, emphasizing that Ukraine should not lose the war for economic reasons.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2023 | 12:22 pm

DARE

Daré Bioscience has achieved its first commercial milestone under a license agreement for XACIATO Vaginal Gel, 2%, an FDA-approved treatment for bacterial vaginosis in females aged 12 years or older.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2023 | 12:21 pm

CATX

Perspective Therapeutics has completed recruitment for the first patient cohort in its Phase 1/2a dose escalation study of 212Pb-VMT01, a targeted alpha-particle therapy for the treatment of MC1R-positive metastatic melanoma. The trial is a multi-center open-label dose escalation, dose expansion study of 212Pb-VMT01 in subjects with histologically confirmed melanoma and positive MC1R imaging scans. The first part of the study is a dose escalation phase to determine the Maximum Tolerated radioactivity Dose (MTD) or Maximum Feasible radioactivity Dose (MFD) following a single administration of 212Pb-VMT01.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2023 | 12:19 pm

TRU

The Federal Housing Finance Agency's (FHFA) proposed change to use two instead of three credit reports during the mortgage application process could result in two million consumers becoming ineligible for a government-sponsored enterprises (GSEs) mortgage, according to an analysis by TransUnion (NYSE:TRU). The change could also lead to 600,000 new mortgage borrowers per year paying more in interest. The most affected consumers are likely to be Black, Hispanic, low-to-moderate income (LMI) and first-time homebuyers. The change could also increase default risk and result in GSEs losing out on $4 billion in risk-based interest fees annually.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2023 | 12:18 pm

SPRC

SciSparc has regained compliance with Nasdaq's minimum bid price requirement. The company had previously received a notification from Nasdaq about its non-compliance.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2023 | 12:17 pm

EQ

Equillium Inc. (NASDAQ:EQ) presented preclinical data on EQ302, a second generation orally deliverable multi-cytokine inhibitor, at the 18th Annual Peptide Therapeutics Symposium. EQ302 is designed to target IL-15 and IL-21 and is being developed for potential use in treating various gastrointestinal diseases. The data showed that EQ302, when administered orally to mice, inhibited IL-15-induced IFNγ transcription in the gastrointestinal tract, indicating potential utility for Celiac Disease and inflammatory bowel disease.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2023 | 12:16 pm

IOVA

Iovance Biotherapeutics has announced clinical data for Lifileucel in advanced mucosal melanoma at the European Society for Medical Oncology Congress. The data is expected to have significant implications for the company's future developments.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2023 | 12:16 pm

OTRK

Ontrak (OTRK) has announced that it has four prospects in the final stage of its sales cycle that could generate growth opportunities in the near future, according to an SEC filing.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2023 | 12:15 pm

TERN

Terns Pharmaceuticals has announced the design of a global Phase 1 clinical trial for TERN-701, a treatment for chronic myeloid leukemia. The U.S. Food and Drug Administration has cleared the Investigational New Drug application. The design is based on insights from an ongoing Phase 1 trial in China. Patient screening is expected to start in December 2023, with initial data expected in the second half of 2024.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2023 | 12:15 pm